PLSE
Pulse Biosciences Inc

1,937
Mkt Cap
$1.22B
Volume
0.00
52W High
$25.00
52W Low
$13.77
PE Ratio
-17.13
PLSE Fundamentals
50D MA
$16.97
Beta
1.22
Avg. Volume
226,072.05
EPS (Annual)
-$0.9176
P/B
11.64
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced the...
Business Wire·20h ago
News Placeholder
More News
News Placeholder
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced it...
Business Wire·2d ago
News Placeholder
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...
Business Wire·9d ago
News Placeholder
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Zacks·12d ago
News Placeholder
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced...
Business Wire·15d ago
News Placeholder
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Zacks·1mo ago
News Placeholder
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.
Zacks·2mo ago
News Placeholder
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced plans to present at the...
Business Wire·8mo ago
News Placeholder
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, today...
Business Wire·9mo ago
News Placeholder
Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, today announced that its nanosecond PFA...
Business Wire·9mo ago

Latest PLSE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.